Global Oral Medicines for Diabetes market size is predicted to grow from US$ 75570 million in 2025 to US$ 141960 million in 2031; it is expected to grow at a CAGR of 11.1% from 2025 to 2031.

Global Oral Medicines for Diabetes Market Size, Share and Analysis

The global Oral Medicines for Diabetes market size is predicted to grow from US$ 75570 million in 2025 to US$ 141960 million in 2031; it is expected to grow at a CAGR of 11.1% from 2025 to 2031. Oral medications for diabetes are medications that are taken by mouth to manage blood sugar levels in people with type 2 diabetes. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs. Infinity Market Research newest research report, the Oral Medicines for Diabetes Industry Forecast looks at past sales and reviews total world Oral Medicines for Diabetes sales in 2024, providing a comprehensive analysis by region and market sector of projected Oral Medicines for Diabetes sales for 2025 through 2031. With Oral Medicines for Diabetes sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Oral Medicines for Diabetes industry. This Insight Report provides a comprehensive analysis of the global Oral Medicines for Diabetes landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Oral Medicines for Diabetes portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms unique position in an accelerating global Oral Medicines for Diabetes market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Oral Medicines for Diabetes and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Oral Medicines for Diabetes. This report presents a comprehensive overview, market shares, and growth opportunities of Oral Medicines for Diabetes market by product type, application, key manufacturers and key regions and countries. Segmentation by Type: &nbsp;&nbsp;&nbsp; Biguanides &nbsp;&nbsp;&nbsp; Sulfonylureas &nbsp;&nbsp;&nbsp; Meglitinides &nbsp;&nbsp;&nbsp; Dipeptidyl Peptidase-4 (DPP-4) Inhibitors &nbsp;&nbsp;&nbsp; SGLT2 Inhibitors &nbsp;&nbsp;&nbsp; Thiazolidinediones &nbsp;&nbsp;&nbsp; Alpha-Glucosidase Inhibitors &nbsp;&nbsp;&nbsp; Other Segmentation by Application: &nbsp;&nbsp;&nbsp; Hospital &nbsp;&nbsp;&nbsp; Clinic &nbsp;&nbsp;&nbsp; Other This report also splits the market by region: &nbsp;&nbsp;&nbsp; Americas &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; United States &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Canada &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mexico &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Brazil &nbsp;&nbsp;&nbsp; APAC &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; China &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Japan &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Korea &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Southeast Asia &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; India &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Australia &nbsp;&nbsp;&nbsp; Europe &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Germany &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; France &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UK &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Italy &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Russia &nbsp;&nbsp;&nbsp; Middle East & Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Egypt &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; South Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Israel &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Turkey &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the companys coverage, product portfolio, its market penetration. &nbsp;&nbsp;&nbsp; Bayer &nbsp;&nbsp;&nbsp; Merck &nbsp;&nbsp;&nbsp; Novartis &nbsp;&nbsp;&nbsp; Huadong Medicine &nbsp;&nbsp;&nbsp; Sanofi &nbsp;&nbsp;&nbsp; Novo Nordisk &nbsp;&nbsp;&nbsp; Servier &nbsp;&nbsp;&nbsp; Takeda Pharmaceutical &nbsp;&nbsp;&nbsp; Luye Pharmaceutical &nbsp;&nbsp;&nbsp; Taiji Group &nbsp;&nbsp;&nbsp; CR Double-Crane &nbsp;&nbsp;&nbsp; AstraZeneca &nbsp;&nbsp;&nbsp; Boehringer Ingelheim &nbsp;&nbsp;&nbsp; Qilu Pharmaceutical &nbsp;&nbsp;&nbsp; Jiangsu Deyuan Pharmaceutical &nbsp;&nbsp;&nbsp; CTTQ Key Questions Addressed in this Report What is the 10-year outlook for the global Oral Medicines for Diabetes market? What factors are driving Oral Medicines for Diabetes market growth, globally and by region? Which technologies are poised for the fastest growth by market and region? How do Oral Medicines for Diabetes market opportunities vary by end market size? How does Oral Medicines for Diabetes break out by Type, by Application?

1 Scope of the Report &nbsp;1.1 Market Introduction &nbsp;1.2 Years Considered &nbsp;1.3 Research Objectives &nbsp;1.4 Market Research Methodology &nbsp;1.5 Research Process and Data Source &nbsp;1.6 Economic Indicators &nbsp;1.7 Currency Considered &nbsp;1.8 Market Estimation Caveats 2 Executive Summary &nbsp;2.1 World Market Overview &nbsp;2.1.1 Global Oral Medicines for Diabetes Annual Sales 2020-2031 &nbsp;2.1.2 World Current & Future Analysis for Oral Medicines for Diabetes by Geographic Region, 2020, 2024 & 2031 &nbsp;2.1.3 World Current & Future Analysis for Oral Medicines for Diabetes by Country/Region, 2020, 2024 & 2031 &nbsp;2.2 Oral Medicines for Diabetes Segment by Type &nbsp;2.2.1 Biguanides &nbsp;2.2.2 Sulfonylureas &nbsp;2.2.3 Meglitinides &nbsp;2.2.4 Dipeptidyl Peptidase-4 (DPP-4) Inhibitors &nbsp;2.2.5 SGLT2 Inhibitors &nbsp;2.2.6 Thiazolidinediones &nbsp;2.2.7 Alpha-Glucosidase Inhibitors &nbsp;2.2.8 Other &nbsp;2.3 Oral Medicines for Diabetes Sales by Type &nbsp;2.3.1 Global Oral Medicines for Diabetes Sales Market Share by Type (2020-2025) &nbsp;2.3.2 Global Oral Medicines for Diabetes Revenue and Market Share by Type (2020-2025) &nbsp;2.3.3 Global Oral Medicines for Diabetes Sale Price by Type (2020-2025) &nbsp;2.4 Oral Medicines for Diabetes Segment by Application &nbsp;2.4.1 Hospital &nbsp;2.4.2 Clinic &nbsp;2.4.3 Other &nbsp;2.5 Oral Medicines for Diabetes Sales by Application &nbsp;2.5.1 Global Oral Medicines for Diabetes Sale Market Share by Application (2020-2025) &nbsp;2.5.2 Global Oral Medicines for Diabetes Revenue and Market Share by Application (2020-2025) &nbsp;2.5.3 Global Oral Medicines for Diabetes Sale Price by Application (2020-2025) 3 Global by Company &nbsp;3.1 Global Oral Medicines for Diabetes Breakdown Data by Company &nbsp;3.1.1 Global Oral Medicines for Diabetes Annual Sales by Company (2020-2025) &nbsp;3.1.2 Global Oral Medicines for Diabetes Sales Market Share by Company (2020-2025) &nbsp;3.2 Global Oral Medicines for Diabetes Annual Revenue by Company (2020-2025) &nbsp;3.2.1 Global Oral Medicines for Diabetes Revenue by Company (2020-2025) &nbsp;3.2.2 Global Oral Medicines for Diabetes Revenue Market Share by Company (2020-2025) &nbsp;3.3 Global Oral Medicines for Diabetes Sale Price by Company &nbsp;3.4 Key Manufacturers Oral Medicines for Diabetes Producing Area Distribution, Sales Area, Product Type &nbsp;3.4.1 Key Manufacturers Oral Medicines for Diabetes Product Location Distribution &nbsp;3.4.2 Players Oral Medicines for Diabetes Products Offered &nbsp;3.5 Market Concentration Rate Analysis &nbsp;3.5.1 Competition Landscape Analysis &nbsp;3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025) &nbsp;3.6 New Products and Potential Entrants &nbsp;3.7 Market M&A Activity & Strategy 4 World Historic Review for Oral Medicines for Diabetes by Geographic Region &nbsp;4.1 World Historic Oral Medicines for Diabetes Market Size by Geographic Region (2020-2025) &nbsp;4.1.1 Global Oral Medicines for Diabetes Annual Sales by Geographic Region (2020-2025) &nbsp;4.1.2 Global Oral Medicines for Diabetes Annual Revenue by Geographic Region (2020-2025) &nbsp;4.2 World Historic Oral Medicines for Diabetes Market Size by Country/Region (2020-2025) &nbsp;4.2.1 Global Oral Medicines for Diabetes Annual Sales by Country/Region (2020-2025) &nbsp;4.2.2 Global Oral Medicines for Diabetes Annual Revenue by Country/Region (2020-2025) &nbsp;4.3 Americas Oral Medicines for Diabetes Sales Growth &nbsp;4.4 APAC Oral Medicines for Diabetes Sales Growth &nbsp;4.5 Europe Oral Medicines for Diabetes Sales Growth &nbsp;4.6 Middle East & Africa Oral Medicines for Diabetes Sales Growth 5 Americas &nbsp;5.1 Americas Oral Medicines for Diabetes Sales by Country &nbsp;5.1.1 Americas Oral Medicines for Diabetes Sales by Country (2020-2025) &nbsp;5.1.2 Americas Oral Medicines for Diabetes Revenue by Country (2020-2025) &nbsp;5.2 Americas Oral Medicines for Diabetes Sales by Type (2020-2025) &nbsp;5.3 Americas Oral Medicines for Diabetes Sales by Application (2020-2025) &nbsp;5.4 United States &nbsp;5.5 Canada &nbsp;5.6 Mexico &nbsp;5.7 Brazil 6 APAC &nbsp;6.1 APAC Oral Medicines for Diabetes Sales by Region &nbsp;6.1.1 APAC Oral Medicines for Diabetes Sales by Region (2020-2025) &nbsp;6.1.2 APAC Oral Medicines for Diabetes Revenue by Region (2020-2025) &nbsp;6.2 APAC Oral Medicines for Diabetes Sales by Type (2020-2025) &nbsp;6.3 APAC Oral Medicines for Diabetes Sales by Application (2020-2025) &nbsp;6.4 China &nbsp;6.5 Japan &nbsp;6.6 South Korea &nbsp;6.7 Southeast Asia &nbsp;6.8 India &nbsp;6.9 Australia &nbsp;6.10 China Taiwan 7 Europe &nbsp;7.1 Europe Oral Medicines for Diabetes by Country &nbsp;7.1.1 Europe Oral Medicines for Diabetes Sales by Country (2020-2025) &nbsp;7.1.2 Europe Oral Medicines for Diabetes Revenue by Country (2020-2025) &nbsp;7.2 Europe Oral Medicines for Diabetes Sales by Type (2020-2025) &nbsp;7.3 Europe Oral Medicines for Diabetes Sales by Application (2020-2025) &nbsp;7.4 Germany &nbsp;7.5 France &nbsp;7.6 UK &nbsp;7.7 Italy &nbsp;7.8 Russia 8 Middle East & Africa &nbsp;8.1 Middle East & Africa Oral Medicines for Diabetes by Country &nbsp;8.1.1 Middle East & Africa Oral Medicines for Diabetes Sales by Country (2020-2025) &nbsp;8.1.2 Middle East & Africa Oral Medicines for Diabetes Revenue by Country (2020-2025) &nbsp;8.2 Middle East & Africa Oral Medicines for Diabetes Sales by Type (2020-2025) &nbsp;8.3 Middle East & Africa Oral Medicines for Diabetes Sales by Application (2020-2025) &nbsp;8.4 Egypt &nbsp;8.5 South Africa &nbsp;8.6 Israel &nbsp;8.7 Turkey &nbsp;8.8 GCC Countries 9 Market Drivers, Challenges and Trends &nbsp;9.1 Market Drivers & Growth Opportunities &nbsp;9.2 Market Challenges & Risks &nbsp;9.3 Industry Trends 10 Manufacturing Cost Structure Analysis &nbsp;10.1 Raw Material and Suppliers &nbsp;10.2 Manufacturing Cost Structure Analysis of Oral Medicines for Diabetes &nbsp;10.3 Manufacturing Process Analysis of Oral Medicines for Diabetes &nbsp;10.4 Industry Chain Structure of Oral Medicines for Diabetes 11 Marketing, Distributors and Customer &nbsp;11.1 Sales Channel &nbsp;11.1.1 Direct Channels &nbsp;11.1.2 Indirect Channels &nbsp;11.2 Oral Medicines for Diabetes Distributors &nbsp;11.3 Oral Medicines for Diabetes Customer 12 World Forecast Review for Oral Medicines for Diabetes by Geographic Region &nbsp;12.1 Global Oral Medicines for Diabetes Market Size Forecast by Region &nbsp;12.1.1 Global Oral Medicines for Diabetes Forecast by Region (2026-2031) &nbsp;12.1.2 Global Oral Medicines for Diabetes Annual Revenue Forecast by Region (2026-2031) &nbsp;12.2 Americas Forecast by Country (2026-2031) &nbsp;12.3 APAC Forecast by Region (2026-2031) &nbsp;12.4 Europe Forecast by Country (2026-2031) &nbsp;12.5 Middle East & Africa Forecast by Country (2026-2031) &nbsp;12.6 Global Oral Medicines for Diabetes Forecast by Type (2026-2031) &nbsp;12.7 Global Oral Medicines for Diabetes Forecast by Application (2026-2031) 13 Key Players Analysis &nbsp;13.1 Bayer &nbsp;13.1.1 Bayer Company Information &nbsp;13.1.2 Bayer Oral Medicines for Diabetes Product Portfolios and Specifications &nbsp;13.1.3 Bayer Oral Medicines for Diabetes Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.1.4 Bayer Main Business Overview &nbsp;13.1.5 Bayer Latest Developments &nbsp;13.2 Merck &nbsp;13.2.1 Merck Company Information &nbsp;13.2.2 Merck Oral Medicines for Diabetes Product Portfolios and Specifications &nbsp;13.2.3 Merck Oral Medicines for Diabetes Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.2.4 Merck Main Business Overview &nbsp;13.2.5 Merck Latest Developments &nbsp;13.3 Novartis &nbsp;13.3.1 Novartis Company Information &nbsp;13.3.2 Novartis Oral Medicines for Diabetes Product Portfolios and Specifications &nbsp;13.3.3 Novartis Oral Medicines for Diabetes Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.3.4 Novartis Main Business Overview &nbsp;13.3.5 Novartis Latest Developments &nbsp;13.4 Huadong Medicine &nbsp;13.4.1 Huadong Medicine Company Information &nbsp;13.4.2 Huadong Medicine Oral Medicines for Diabetes Product Portfolios and Specifications &nbsp;13.4.3 Huadong Medicine Oral Medicines for Diabetes Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.4.4 Huadong Medicine Main Business Overview &nbsp;13.4.5 Huadong Medicine Latest Developments &nbsp;13.5 Sanofi &nbsp;13.5.1 Sanofi Company Information &nbsp;13.5.2 Sanofi Oral Medicines for Diabetes Product Portfolios and Specifications &nbsp;13.5.3 Sanofi Oral Medicines for Diabetes Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.5.4 Sanofi Main Business Overview &nbsp;13.5.5 Sanofi Latest Developments &nbsp;13.6 Novo Nordisk &nbsp;13.6.1 Novo Nordisk Company Information &nbsp;13.6.2 Novo Nordisk Oral Medicines for Diabetes Product Portfolios and Specifications &nbsp;13.6.3 Novo Nordisk Oral Medicines for Diabetes Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.6.4 Novo Nordisk Main Business Overview &nbsp;13.6.5 Novo Nordisk Latest Developments &nbsp;13.7 Servier &nbsp;13.7.1 Servier Company Information &nbsp;13.7.2 Servier Oral Medicines for Diabetes Product Portfolios and Specifications &nbsp;13.7.3 Servier Oral Medicines for Diabetes Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.7.4 Servier Main Business Overview &nbsp;13.7.5 Servier Latest Developments &nbsp;13.8 Takeda Pharmaceutical &nbsp;13.8.1 Takeda Pharmaceutical Company Information &nbsp;13.8.2 Takeda Pharmaceutical Oral Medicines for Diabetes Product Portfolios and Specifications &nbsp;13.8.3 Takeda Pharmaceutical Oral Medicines for Diabetes Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.8.4 Takeda Pharmaceutical Main Business Overview &nbsp;13.8.5 Takeda Pharmaceutical Latest Developments &nbsp;13.9 Luye Pharmaceutical &nbsp;13.9.1 Luye Pharmaceutical Company Information &nbsp;13.9.2 Luye Pharmaceutical Oral Medicines for Diabetes Product Portfolios and Specifications &nbsp;13.9.3 Luye Pharmaceutical Oral Medicines for Diabetes Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.9.4 Luye Pharmaceutical Main Business Overview &nbsp;13.9.5 Luye Pharmaceutical Latest Developments &nbsp;13.10 Taiji Group &nbsp;13.10.1 Taiji Group Company Information &nbsp;13.10.2 Taiji Group Oral Medicines for Diabetes Product Portfolios and Specifications &nbsp;13.10.3 Taiji Group Oral Medicines for Diabetes Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.10.4 Taiji Group Main Business Overview &nbsp;13.10.5 Taiji Group Latest Developments &nbsp;13.11 CR Double-Crane &nbsp;13.11.1 CR Double-Crane Company Information &nbsp;13.11.2 CR Double-Crane Oral Medicines for Diabetes Product Portfolios and Specifications &nbsp;13.11.3 CR Double-Crane Oral Medicines for Diabetes Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.11.4 CR Double-Crane Main Business Overview &nbsp;13.11.5 CR Double-Crane Latest Developments &nbsp;13.12 AstraZeneca &nbsp;13.12.1 AstraZeneca Company Information &nbsp;13.12.2 AstraZeneca Oral Medicines for Diabetes Product Portfolios and Specifications &nbsp;13.12.3 AstraZeneca Oral Medicines for Diabetes Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.12.4 AstraZeneca Main Business Overview &nbsp;13.12.5 AstraZeneca Latest Developments &nbsp;13.13 Boehringer Ingelheim &nbsp;13.13.1 Boehringer Ingelheim Company Information &nbsp;13.13.2 Boehringer Ingelheim Oral Medicines for Diabetes Product Portfolios and Specifications &nbsp;13.13.3 Boehringer Ingelheim Oral Medicines for Diabetes Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.13.4 Boehringer Ingelheim Main Business Overview &nbsp;13.13.5 Boehringer Ingelheim Latest Developments &nbsp;13.14 Qilu Pharmaceutical &nbsp;13.14.1 Qilu Pharmaceutical Company Information &nbsp;13.14.2 Qilu Pharmaceutical Oral Medicines for Diabetes Product Portfolios and Specifications &nbsp;13.14.3 Qilu Pharmaceutical Oral Medicines for Diabetes Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.14.4 Qilu Pharmaceutical Main Business Overview &nbsp;13.14.5 Qilu Pharmaceutical Latest Developments &nbsp;13.15 Jiangsu Deyuan Pharmaceutical &nbsp;13.15.1 Jiangsu Deyuan Pharmaceutical Company Information &nbsp;13.15.2 Jiangsu Deyuan Pharmaceutical Oral Medicines for Diabetes Product Portfolios and Specifications &nbsp;13.15.3 Jiangsu Deyuan Pharmaceutical Oral Medicines for Diabetes Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.15.4 Jiangsu Deyuan Pharmaceutical Main Business Overview &nbsp;13.15.5 Jiangsu Deyuan Pharmaceutical Latest Developments &nbsp;13.16 CTTQ &nbsp;13.16.1 CTTQ Company Information &nbsp;13.16.2 CTTQ Oral Medicines for Diabetes Product Portfolios and Specifications &nbsp;13.16.3 CTTQ Oral Medicines for Diabetes Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.16.4 CTTQ Main Business Overview &nbsp;13.16.5 CTTQ Latest Developments 14 Research Findings and Conclusion

Report	Global Oral Medicines for Diabetes Market Growth, Trends and Opportunities 2025-31
Selected License	Multi ID: LPI49816

Buyer Information

Order Summary